CorMedix Inc (CRMD) has been under a strong bear grip, hence the stock is down -2.71% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 13.75% in the past 1 week. The stock has risen by 13.82% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.7% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 13.07% and the 50-Day Moving Average is 8.04%. CorMedix Inc (NYSEMKT:CRMD): On Fridays trading session , Opening price of the stock was $1.8 with an intraday high of $1.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.63. However, the stock managed to close at $1.73, a loss of 1.70% for the day. On the previous day, the stock had closed at $1.76. The total traded volume of the day was 592,667 shares.
The company Insiders own 10.4% of CorMedix Inc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -24.25% . Institutional Investors own 21.39% of CorMedix Inc shares. During last six month period, the net percent change held by insiders has seen a change of -24.25%.
CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Companys primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.